Core Viewpoint - Changshan Pharmaceutical has received approval for clinical trials of Aibennapeptide injection for weight loss indications, marking a significant step in its drug development process [1] Company Summary - Changshan Pharmaceutical (300255.SZ) and its subsidiary Changshan Kaijiejian have obtained the clinical trial approval notice from the National Medical Products Administration for Aibennapeptide injection [1] - Aibennapeptide is a long-acting glucagon-like peptide-1 receptor agonist that stimulates insulin secretion and inhibits glucagon secretion in a glucose-dependent manner, while also promoting glucose uptake in muscle and fat tissues and suppressing hepatic glucose production [1] - The approval for clinical trials does not have a significant impact on the company's recent performance, as further clinical trials and regulatory reviews are required before the drug can be marketed [1] Industry Summary - The drug development process is characterized by high investment, long cycles, and significant risks, with various uncertainties affecting clinical trial outcomes and market competition [1] - The approval of clinical trials is just the beginning, as the drug must undergo further testing and regulatory scrutiny before it can be launched in the market [1]

Market Overview - On June 19, A-shares opened lower and continued to decline, with the Shanghai Composite Index falling by 0.79% to 3362 points, the Shenzhen Component Index down by 1.21%, and the ChiNext Index down by 1.36%, with over 4600 stocks declining across the market [1] - Market focus shifted towards the oil, natural gas, and digital reading sectors [1] High-Performing Stocks - In the oil and gas sector, Zhuan Oil Co. and Shandong Molong achieved five consecutive trading limits, while military stock Beifang Changlong saw a 20% increase over three days [3] - Notable stocks with significant gains include: - Shandong Quanlong: +10.00%, five consecutive limits [4] - Zhuan Oil Co.: +9.96%, five consecutive limits [4] - Beifang Changlong: +20.01%, three limits in five days [4] - Innovation Medical: +10.04%, two limits in three days [4] Trading Activity - The top three net purchases on the Dragon and Tiger list were: - Innovation Medical: net purchase of 207 million [5] - Electric Science Cybersecurity: net purchase of 153 million [5] - Anni Co.: net purchase of 135 million [5] - The top three net sales were: - Limin Co.: net sale of 230 million [7] - Xiexin Energy: net sale of 218 million [7] - Changshan Pharmaceutical: net sale of 178 million [7] Sector Highlights - Innovation Medical focuses on brain-machine interfaces and AI medical models, achieving a trading limit with a turnover of 1.745 billion and a turnover rate of 31.78% [10] - Baida Qiancheng, involved in short drama games and major contract signings, also reached a trading limit with a turnover of 1.077 billion [14] - Electric Science Cybersecurity, which focuses on digital currency and satellite navigation, achieved a trading limit with a turnover of 694 million [18] Institutional Activity - Institutions showed significant interest in several stocks, with net purchases in: - Electric Science Cybersecurity: 35 million [22] - Innovation Medical: 26 million [22] - Shandong Molong: 20 million [22] - Conversely, institutions sold off stocks like Limin Co. and Xiexin Energy, with net sales of 64 million and 71 million respectively [19][22] Conclusion - The market experienced a downward trend with specific sectors like oil and gas showing resilience through notable stock performances. Institutional trading patterns indicate selective interest in high-growth potential stocks, particularly in the technology and healthcare sectors.

Group 1 - The stock of Changshan Pharmaceutical experienced a limit down, with a trading volume of 33.95 billion and a turnover rate of 7.18%, reflecting a price drop of 20.00% at the close [2] - Institutional investors net sold 97.06 million, while the Shenzhen Stock Connect recorded a net sell of 74.57 million [2] - The top five trading departments accounted for a total transaction of 699 million, with a net sell of 17.8 million [2][3] Group 2 - Over the past six months, the stock has appeared on the trading leaderboard five times, with an average price increase of 3.12% the day after being listed and an average increase of 6.28% over the following five days [3] - The stock saw a net outflow of 617 million in principal funds today, with large orders contributing to a net outflow of 565 million [3] - The trading data shows that the top buying and selling departments included the Shenzhen Stock Connect, which was both the largest buyer and seller, with buying and selling amounts of 95.96 million and 171 million respectively [3][4]

暗盘资金正涌入这些股票，点击速看>>> 常山药业（300255）今日跌停，成交额33.95亿元，换手率7.18%，盘后龙虎榜数据显示，深股通专用席 位买入9596.40万元并卖出1.71亿元，三机构专用席位净卖出9705.97万元。 ...

Market Overview - A-share market experienced a "high-low switch" with strong sectors like innovative drugs, controllable nuclear fusion, and digital currency facing adjustments, while previously weak humanoid robot sector rebounded significantly [1][2] - High-position stocks faced significant fluctuations, with companies like Changshan Pharmaceutical and Yong'an Pharmaceutical hitting the daily limit down, contributing to a 1.98% drop in the micro-cap stock index [2] Index Performance - As of the morning close, the Shanghai Composite Index fell by 0.86% to 3359.78, the Shenzhen Component Index decreased by 1.01% to 10072.42, and the ChiNext Index dropped by 1.1% to 2032.19 [3] Innovative Drug Sector - The innovative drug sector saw a pullback, with Changshan Pharmaceutical hitting a 20% daily limit down and other stocks like Hanyu Pharmaceutical also experiencing significant declines [5][6] - Despite the current adjustments, institutions remain optimistic about the innovative drug sector's investment opportunities in the second half of the year, citing supportive policies and improving fundamentals [8] Solid-State Battery Sector - The solid-state battery sector showed strong performance in the morning, with stocks like Haike Xinyuan and others experiencing significant gains [10] - Key factors driving the solid-state battery sector include policy support, breakthroughs in research by leading battery manufacturers, continuous optimization of equipment, and unexpected commercial progress [11][12][13]

Market Overview - The three major indices experienced a decline, with the ChiNext Index dropping by 1.1% and over 4600 stocks in the market showing negative performance [1][3] - The Shanghai Composite Index fell by 0.86%, the Shenzhen Component Index decreased by 1.01%, and the North China 50 Index also saw a nearly 1% drop, with trading volume exceeding 800 billion, an increase of over 40 billion compared to the previous day [3] Economic Factors - Recent macroeconomic data has shown signs of pressure, leading to hesitance in market recovery expectations [3] - Popular sectors such as AI and weight-loss drugs are experiencing corrections, prompting funds to shift towards defensive sectors [3] - External market instability has also contributed to negative sentiment in the domestic market [3] Sector Performance - Solid-state batteries, PCB, and oil sectors saw gains, with stocks like Nord and Xiangtan Electric achieving limit-up [3] - The solid-state battery sector is gaining attention due to recent technological breakthroughs and a reasonable valuation after previous adjustments in the new energy sector [3] - The oil sector's rise may be linked to geopolitical tensions in the Middle East, particularly the potential for U.S. actions against Iran, leading to short-term oil price volatility [3] Declining Sectors - The nuclear fusion, military, and weight-loss drug sectors faced significant declines, with Changshan Pharmaceutical hitting the limit down and Hanyu Pharmaceutical dropping over 10% [4] - The military sector's adjustment is attributed to a lack of new catalysts, leading to fund withdrawals [4] - The nuclear power sector saw stocks like Hezhan Intelligent and China Nuclear Technology hitting the limit down, possibly due to negative news from specific companies [4] Investment Strategy - In a broad market decline, it is essential to maintain a calm mindset and focus on identifying quality stocks [4] - Long-term investors should prioritize company fundamentals and industry prospects over short-term price fluctuations [4] - The solid-state battery sector is highlighted as a promising long-term investment, while caution is advised in the weight-loss drug sector due to speculative trading [4]

智通财经6月19日电，早盘创新药概念延续调整，常山药业触及20CM跌停，翰宇药业跌超10%，通化金 马、广生堂、赛升药业、舒泰神等跟跌。 创新药概念延续调整 常山药业触及跌停 ...

常山药业跳水，一度触及跌停，现跌幅收窄至17%，成交额超17亿元。 ...

Group 1 - The chemical pharmaceutical sector has experienced a short-term decline, with Changshan Pharmaceutical (300255) dropping over 12% [1] - Other companies such as Yong'an Pharmaceutical (002365), Hanyu Pharmaceutical (300199), Tonghua Jinma (000766), and Guangshengtang (300436) also saw declines [1] - There is an influx of dark pool funds entering these stocks [1]

Market Overview - The market saw a slight overall increase, with the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index rising by 0.04%, 0.24%, and 0.23% respectively, while nearly 3,500 stocks declined and about 1,800 stocks rose [4] Stablecoin - Stablecoin concepts are gaining traction, with JD Group's chairman expressing intentions to apply for stablecoin licenses globally to reduce cross-border payment costs by 90% and improve efficiency to under 10 seconds [7] - The People's Bank of China governor highlighted the role of blockchain and distributed ledger technology in enhancing the development of central bank digital currencies and stablecoins, indicating a growing global demand for improved cross-border payment systems [7][8] - Traditional cross-border payment systems are slow, taking 3-5 business days on average, while stablecoins can facilitate direct peer-to-peer settlements, potentially replacing traditional methods in the future [8] Methanol - Methanol stocks are performing well, with Jin Niu Chemical achieving a four-day consecutive increase, driven by strong demand from major production and export regions like Iran amidst geopolitical tensions [9][11] - The market dynamics show a divergence in performance, with some stocks like Jiang Tian Chemical experiencing significant declines while others thrive [14] Military Industry - The military sector is showing strength, with several stocks like Changcheng Military Industry and New Light Optoelectronics hitting their daily limits, driven by ongoing tensions in the Middle East [15][17] - The military sector index rose by 0.68%, reflecting a correlation with oil and gas sectors due to geopolitical factors [17] Innovative Pharmaceuticals - The innovative pharmaceutical sector is experiencing a pullback, with leading stocks like Shutai Shen facing declines, while Changshan Pharmaceutical saw a significant increase of nearly 15%, marking a 200% rise year-to-date [20] - The stock has shown a tenfold increase over two and a half years, indicating strong market interest in weight-loss drugs [20]